JÃ¶rg H W Distler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1153202/publications.pdf

Version: 2024-02-01

224	30,349	10351 72	5364 164
papers	citations	h-index	g-index

225	225	225	42910
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Response to: â€˜Correspondence on â€˜Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosisâ€™â€™ by Jenyet al. Annals of the Rheumatic Diseases, 2022, 81, e242-e242.	0.5	5
2	Platelet Phagocytosis via Pâ€selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 318-328.	2.9	12
3	Nintedanib in Patients With Systemic Sclerosisâ€“Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis and Rheumatology, 2022, 74, 518-526.	2.9	21
4	Impaired Mitochondrial Transcription Factor A Expression Promotes Mitochondrial Damage to Drive Fibroblast Activation and Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 871-881.	2.9	5
5	Epigenetic profiling of twins identify repression of KLF4 as a novel pathomechanism in systemic sclerosis. Annals of the Rheumatic Diseases, 2022, 81, 151-152.	0.5	1
6	LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis. Clinical and Translational Medicine, 2022, 12, e711.	1.7	14
7	The role of antifibrotics in the treatment of rheumatoid arthritisâ€“associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210744.	1.2	7
8	Nintedanib in Patients With Autoimmune Diseaseâ€“Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <scp>INBUILD</scp> Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	2.9	44
9	Patient's Perception of Digital Symptom Assessment Technologies in Rheumatology: Results From a Multicentre Study. Frontiers in Public Health, 2022, 10, 844669.	1.3	17
10	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	0.9	6
11	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	0.9	20
12	Genetic Associations of Nonâ€“Major Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population. Journal of Investigative Dermatology, 2022, 142, 2039-2042.e7.	0.3	0
13	Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respiratory Research, 2022, 23, .	1.4	1
14	Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Annals of the Rheumatic Diseases, 2021, 80, e87-e87.	0.5	15
15	Reply. Arthritis and Rheumatology, 2021, 73, 179-180.	2.9	1
16	Cellular and molecular mechanisms in fibrosis. Experimental Dermatology, 2021, 30, 121-131.	1.4	39
17	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports, 2021, 11, 1.	1.6	9,439
18	Mouse Models of Skin Fibrosis. Methods in Molecular Biology, 2021, 2299, 371-383.	0.4	4

#	Article	IF	Citations
19	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	5.2	118
20	Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. Annals of the Rheumatic Diseases, 2021, 80, 920-929.	0.5	23
21	68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatology, The, 2021, 3, e185-e194.	2.2	46
22	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatology, The, 2021, 3, e175-e184.	2.2	13
23	X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc). Annals of the Rheumatic Diseases, 2021, 80, 1048-1056.	0.5	3
24	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. Blood, 2021, 137, 2403-2416.	0.6	11
25	Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial. Arthritis Research and Therapy, 2021, 23, 112.	1.6	40
26	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	1.4	5
27	Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis. Frontiers in Cell and Developmental Biology, 2021, 9, 681061.	1.8	13
28	Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease â€“ Authors' reply. Lancet Rheumatology, The, 2021, 3, e475-e477.	2.2	0
29	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. Arthritis Research and Therapy, 2021, 23, 204.	1.6	8
30	TGFÎ² promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. Nature Communications, 2021, 12, 4404.	5.8	40
31	Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. Journal of Experimental Medicine, 2021, 218, .	4.2	16
32	Purinergic signaling in systemic sclerosis. Rheumatology, 2021, , .	0.9	0
33	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 134-141.	0.4	1
34	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2021, 39, 134-141.	0.4	3
35	Comment on: â€˜Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteriaâ€™ by Greco et al. Annals of the Rheumatic Diseases, 2020, 79, e85-e85.	0.5	7
36	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 137-149.	2.9	75

#	ARTICLE	IF	CITATIONS
37	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	0.9	27
38	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. Science Translational Medicine, 2020, 12, .	5.8	26
39	Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Annals of the Rheumatic Diseases, 2020, 79, 1485-1491.	0.5	111
40	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. Rheumatology, 2020, 59, 3939-3951.	0.9	5
41	PGC-1Î± regulates autophagy to promote fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2020, 79, 1227-1233.	0.5	19
42	Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1385-1395.	2.9	13
43	Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS ONE, 2020, 15, e0229445.	1.1	23
44	The Î±7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders. Journal of Investigative Dermatology, 2020, 140, 2371-2379.	0.3	7
45	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. British Journal of Pharmacology, 2020, 177, 4296-4309.	2.7	19
46	Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal, 2020, 55, 1902026.	3.1	134
47	microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4. Biochemical and Biophysical Research Communications, 2020, 523, 1001-1006.	1.0	10
48	Therapeutic molecular targets of SSc-ILD. Journal of Scleroderma and Related Disorders, 2020, 5, 17-30.	1.0	6
49	TGF-Î²â€“induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. Journal of Clinical Investigation, 2020, 130, 2347-2363.	3.9	76
50	Long noncoding RNA H19X is a key mediator of TGF-Î²â€“driven fibrosis. Journal of Clinical Investigation, 2020, 130, 4888-4905.	3.9	52
51	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical Rheumatology, 2019, 38, 2673-2681.	1.0	38
52	Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. Journal of Controlled Release, 2019, 310, 198-208.	4.8	36
53	Regulation of Fibroblast Apoptosis and Proliferation by Micro RNA â€125b in Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 2068-2080.	2.9	14
54	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2019, 54, 1900161.	3.1	164

#	Article	IF	Citations
55	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, 2019, 10, 4955.	5.8	100
56	Shared and distinct mechanisms of fibrosis. Nature Reviews Rheumatology, 2019, 15, 705-730.	3.5	331
57	PU.1 controls fibroblast polarization and tissue fibrosis. Nature, 2019, 566, 344-349.	13.7	121
58	Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. Journal of Investigative Dermatology, 2019, 139, 439-447.	0.3	17
59	Acyltransferase skinny hedgehog regulates TGFÎ²-dependent fibroblast activation in SSc. Annals of the Rheumatic Diseases, 2019, 78, 1269-1273.	0.5	16
60	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosisâ€“associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2019, 4, 212-218.	1.0	31
61	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.5	142
62	SAT0271â€…RELATIONSHIP BETWEEN ANTI-MDA5 ANTIBODIES AND CANCER: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL AND MULTIDISCIPLINARY COHORT. , 2019, , .		0
63	SAT0001â€…FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY. , 2019, , .		0
64	OP0184â€…PROFIBROTIC LNCRNA H19X: UNRAVELLING THE EFFECTS ON CHROMATIN REMODELING IN SYSTEMIC SCLEROSIS FIBROBLASTS. , 2019, , .		0
65	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.5	13
66	Possible adaptations of vascularised human skin equivalents to include rare cell populations and study fibroblast heterogeneity. Response to: â€˜In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?â€™ by Manetti and Matucci-Cerinic. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216393.	0.5	1
67	Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Annals of the Rheumatic Diseases, 2019, 78, 1686-1692.	0.5	32
68	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
69	Targeting TGF-Î² signaling for the treatment of fibrosis. Matrix Biology, 2018, 68-69, 8-27.	1.5	196
70	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 744-751.	0.5	36
71	Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis. Journal of Immunology, 2018, 200, 1249-1254.	0.4	74
72	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Annals of the Rheumatic Diseases, 2018, 77, 459-459.	0.5	33

#	Article	IF	Citations
73	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.5	50
74	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53
75	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 626-628.	0.5	12
76	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 150-158.	0.5	51
77	Innate lymphoid cells and fibrotic regulation. Immunology Letters, 2018, 195, 38-44.	1.1	13
78	NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover. Journal of Bone and Mineral Research, 2018, 33, 2035-2047.	3.1	15
79	Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 989.	2.2	9
80	The tyrosine phosphatase SHP2 controls TGFÎ²-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nature Communications, 2018, 9, 3259.	5.8	89
81	Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling. Annals of the Rheumatic Diseases, 2017, 76, 773-778.	0.5	22
82	Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Annals of the Rheumatic Diseases, 2017, 76, 1133-1141.	0.5	66
83	The transcription factor GLI2 as a downstream mediator of transforming growth factor-Î²-induced fibroblast activation in SSc. Annals of the Rheumatic Diseases, 2017, 76, 756-764.	0.5	53
84	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2017, 76, 244-251.	0.5	28
85	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
86	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Annals of the Rheumatic Diseases, 2017, 76, 1467-1475.	0.5	41
87	Epigenetic factors as drivers of fibrosis in systemic sclerosis. Epigenomics, 2017, 9, 463-477.	1.0	32
88	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
89	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nature Communications, 2017, 8, 1130.	5.8	245
90	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.5	410

#	ARTICLE	IF	CITATIONS
91	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1941-1948.	0.5	149
92	Tie2 as a novel key factor of microangiopathy in systemic sclerosis. Arthritis Research and Therapy, 2017, 19, 105.	1.6	25
93	Targeting of <scp>NADPH</scp> oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Experimental Dermatology, 2017, 26, 73-81.	1.4	30
94	Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 257-267.	2.9	62
95	Overview of Animal Models. , 2017, , 281-293.		1
96	Sirt1 regulates canonical TGF-Î² signalling to control fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 226-233.	0.5	115
97	Emerging strategies for treatment of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 186-193.	1.0	41
98	Updates on animal models of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 266-276.	1.0	14
99	Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 2037-2044.	0.5	29
100	Tocilizumab for systemic sclerosis: implications for future trials. Lancet, The, 2016, 387, 2580-2581.	6.3	13
101	Evidence of innate lymphoid cell redundancy in humans. Nature Immunology, 2016, 17, 1291-1299.	7.0	260
102	Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	2.9	46
103	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Annals of the Rheumatic Diseases, 2016, 75, 303-310.	0.5	45
104	Tribbles homologue 3 stimulates canonical TGF-Î² signalling to regulate fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 609-616.	0.5	38
105	Canonical Wnt signaling in systemic sclerosis. Laboratory Investigation, 2016, 96, 151-155.	1.7	52
106	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
107	Influence ofTYK2in systemic sclerosis susceptibility: a newlocusin the IL-12 pathway. Annals of the Rheumatic Diseases, 2016, 75, 1521-1526.	0.5	41
108	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.5	56

#	ARTICLE	IF	CITATIONS
109	Activating transcription factor 3 regulates canonical TGFÎ² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 586-592.	0.5	28
110	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 623-626.	0.5	78
111	Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. Annals of the Rheumatic Diseases, 2016, 75, 1203-1210.	0.5	98
112	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 883-890.	0.5	154
113	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 2016, 11, e0163894.	1.1	158
114	Inhibition of casein kinase II reduces TGFÎ² induced fibroblast activation and ameliorates experimental fibrosis. Annals of the Rheumatic Diseases, 2015, 74, 936-943.	0.5	45
115	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFÎ² signalling. Annals of the Rheumatic Diseases, 2015, 74, 1408-1416.	0.5	92
116	Orphan nuclear receptor NR4A1 regulates transforming growth factor-Î² signaling and fibrosis. Nature Medicine, 2015, 21, 150-158.	15.2	267
117	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	0.9	17
118	From pathogenesis to therapy â€“ Perspective on treatment strategies in fibrotic diseases. Pharmacological Research, 2015, 100, 93-100.	3.1	17
119	Cardiomyopathy in Murine Models of Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 508-516.	2.9	39
120	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Annals of the Rheumatic Diseases, 2015, 74, 1621-1625.	0.5	60
121	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases, 2015, 74, 1317-1324.	0.5	28
122	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases, 2015, 74, 1188-1194.	0.5	340
123	S100A4 amplifies TGF-Î²-induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1748-1755.	0.5	52
124	Vitamin D receptor regulates TGF-Î² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, e20-e20.	0.5	111
125	Antiâ€Fibrotic Effect of Ajulemic Acid in Bleomycinâ€Induced Lung Fibrosis. FASEB Journal, 2015, 29, LB744.	0.2	0
126	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.4	4

#	ARTICLE	IF	CITATIONS
127	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clinical and Experimental Rheumatology, 2015, 33, S75-9.	0.4	13
128	Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 1880-1887.	0.5	69
129	The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor Î² and Contributes to the Development of Experimental Dermal Fibrosis. Arthritis and Rheumatology, 2014, 66, 3140-3150.	2.9	13
130	Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Annals of the Rheumatic Diseases, 2014, 73, 1264-1268.	0.5	32
131	The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 1232-1239.	0.5	166
132	Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Annals of the Rheumatic Diseases, 2014, 73, 624-627.	0.5	26
133	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	2.6	182
134	A3.19â€…mIR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways. Annals of the Rheumatic Diseases, 2014, 73, A49.2-A49.	0.5	0
135	Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?. Current Opinion in Pharmacology, 2013, 13, 455-462.	1.7	16
136	Activation of pregnane X receptor inhibits experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 621-625.	0.5	22
137	Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Archives of Dermatological Research, 2013, 305, 1-8.	1.1	25
138	Changing paradigms in spondylarthritis: The myofibroblast signature. Arthritis and Rheumatism, 2013, 65, 24-27.	6.7	7
139	The Fra-2 transgenic mouse model of systemic sclerosis. Vascular Pharmacology, 2013, 58, 194-201.	1.0	54
140	Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 614-620.	0.5	93
141	Morphogen Pathways in Systemic Sclerosis. Current Rheumatology Reports, 2013, 15, 299.	2.1	23
142	Tyrosine kinase signaling in fibrotic disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 897-904.	1.8	103
143	Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Annals of the Rheumatic Diseases, 2013, 72, 1575-1580.	0.5	69
144	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 1255-1258.	0.5	98

#	ARTICLE	IF	CITATIONS
145	Canonical <scp>Wnt</scp> signalling as a key regulator of fibrogenesis â€“ implications for targeted therapies?. Experimental Dermatology, 2013, 22, 710-713.	1.4	49
146	Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Annals of the Rheumatic Diseases, 2013, 72, 2039-2046.	0.5	20
147	New insight on the Xq28 association with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 2032-2038.	0.5	52
148	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 1089-1098.	0.5	35
149	Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover. Journal of Bone and Mineral Research, 2013, 28, 936-947.	3.1	12
150	Autophagy. Autophagy, 2013, 9, 1253-1255.	4.3	61
151	A8.3â€...Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. Annals of the Rheumatic Diseases, 2013, 72, A58.1-A58.	0.5	0
152	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS ONE, 2013, 8, e54419.	1.1	38
153	The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1081-1087.	0.5	35
154	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 2012, 21, 926-933.	1.4	74
155	Innovative antifibrotic therapies in systemic sclerosis. Current Opinion in Rheumatology, 2012, 24, 274-280.	2.0	48
156	Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 1545-1551.	0.5	87
157	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 737-745.	0.5	53
158	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 785-789.	0.5	73
159	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1019-1026.	0.5	74
160	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1895-1899.	0.5	31
161	Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. Annals of the Rheumatic Diseases, 2012, 71, 2051-2054.	0.5	26
162	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	1.4	98

#	ARTICLE	IF	CITATIONS
163	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood, 2012, 120, 2909-2917.	0.6	53
164	Inhibition of sumoylation prevents experimental fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1904-1908.	0.5	28
165	Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 2294-2302.	1.0	34
166	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 1382-1387.	0.5	93
167	JAKâ€2 as a novel mediator of the profibrotic effects of transforming growth factor Î² in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 3006-3015.	6.7	115
168	Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease. American Journal of Pathology, 2012, 181, 1672-1680.	1.9	28
169	Activation of canonical Wnt signalling is required for TGF-Î²-mediated fibrosis. Nature Communications, 2012, 3, 735.	5.8	649
170	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. Journal of Bone and Mineral Research, 2012, 27, 575-585.	3.1	100
171	Inhibition of activator protein 1 signaling abrogates transforming growth factor Î²â€“mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 2012, 64, 1642-1652.	6.7	81
172	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 2724-2733.	6.7	133
173	Î²-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 761-767.	0.5	174
174	Inhibition of glycogen synthase kinase 3Â induces dermal fibrosis by activation of the canonical Wnt pathway. Annals of the Rheumatic Diseases, 2011, 70, 2191-2198.	0.5	96
175	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1304-1310.	0.5	116
176	Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts. Journal of Cellular and Molecular Medicine, 2011, 15, 756-762.	1.6	45
177	Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials. Current Rheumatology Reports, 2011, 13, 21-27.	2.1	41
178	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 800-809.	6.7	73
179	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis and Rheumatism, 2011, 63, 1396-1404.	6.7	107
180	Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis and Rheumatism, 2011, 63, 2067-2077.	6.7	36

#	ARTICLE	IF	CITATIONS
181	The transcription factor JunD mediates transforming growth factor Â-induced fibroblast activation and fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1320-1326.	0.5	59
182	Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine, 2011, 208, 961-972.	4.2	222
183	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. PLoS Genetics, 2011, 7, e1002091.	1.5	205
184	Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Annals of the Rheumatic Diseases, 2011, 70, 1197-1202.	0.5	21
185	The transcription factor Fraâ€2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 280-290.	6.7	97
186	Decreased lymphatic vessel counts in patients with systemic sclerosis: Association with fingertip ulcers. Arthritis and Rheumatism, 2010, 62, 1513-1522.	6.7	22
187	MicroRNAâ€29, a key regulator of collagen expression in systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 1733-1743.	6.7	470
188	Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis and Rheumatism, 2010, 62, 3467-3476.	6.7	67
189	Animal models of systemic sclerosis: Prospects and limitations. Arthritis and Rheumatism, 2010, 62, 2831-2844.	6.7	135
190	Microparticles and their roles in inflammatory arthritides. Nature Reviews Rheumatology, 2010, 6, 385-386.	3.5	27
191	Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis. Circulation, 2009, 120, 2367-2376.	1.6	105
192	Lack of inhibitory effects of the antiâ€fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. Journal of Cellular and Molecular Medicine, 2009, 13, 4185-4191.	1.6	11
193	Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis and Rheumatism, 2009, 60, 219-224.	6.7	187
194	Stimulatory autoantibodies to plateletâ€derived growth factor receptors in systemic sclerosis: What functional autoimmunity could learn from receptor biology. Arthritis and Rheumatism, 2009, 60, 907-911.	6.7	35
195	The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis and Rheumatism, 2009, 60, 1129-1136.	6.7	106
196	Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis and Rheumatism, 2009, 60, 1519-1529.	6.7	100
197	Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases. Arthritis and Rheumatism, 2009, 60, 3168-3179.	6.7	39
198	Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblastâ€“dependent osteoclastogenesis. Arthritis and Rheumatism, 2009, 60, 3663-3675.	6.7	14

#	ARTICLE	IF	CITATIONS
199	Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Research and Therapy, 2009, 11, 220.	1.6	99
200	The scientific basis for novel treatments of systemic sclerosis. F1000 Medicine Reports, 2009, 1, .	2.9	3
201	Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis. Arthritis and Rheumatism, 2008, 58, 1475-1484.	6.7	111
202	Rhoâ€associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis and Rheumatism, 2008, 58, 2553-2564.	6.7	102
203	Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis and Rheumatism, 2008, 58, 2538-2542.	6.7	43
204	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism, 2008, 58, 2845-2853.	6.7	91
205	Novel Treatment Approaches to Fibrosis in Scleroderma. Rheumatic Disease Clinics of North America, 2008, 34, 145-159.	0.8	16
206	Dual inhibition of câ€abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB Journal, 2008, 22, 2214-2222.	0.2	179
207	Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. Nature Clinical Practice Rheumatology, 2008, 4, 160-164.	3.2	2
208	Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?. Annals of the Rheumatic Diseases, 2007, 66, 836-836.	0.5	15
209	Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis and Rheumatism, 2007, 56, 311-322.	6.7	358
210	Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycinâ€induced skin fibrosis. Arthritis and Rheumatism, 2007, 56, 2755-2764.	6.7	153
211	Microparticles stimulate the synthesis of prostaglandin E₂ via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis and Rheumatism, 2007, 56, 3564-3574.	6.7	82
212	Hypoxiaâ€induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 4203-4215.	6.7	168
213	The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 363-374.	2.2	54
214	Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis and Rheumatism, 2006, 54, 214-225.	6.7	89
215	Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity, 2006, 39, 683-690.	1.2	154
216	Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*. Experimental Dermatology, 2005, 14, 315-320.	1.4	51

#	ARTICLE	IF	CITATIONS
217	Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis and Rheumatism, 2005, 52, 856-864.	6.7	127
218	Microparticles as regulators of inflammation: Novel players of cellular crosstalk in the rheumatic diseases. Arthritis and Rheumatism, 2005, 52, 3337-3348.	6.7	215
219	The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2892-2897.	3.3	368
220	Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-ÎºB and Simian Virus 40 Promoter Factor 1 Pathways. Molecular Pharmacology, 2004, 65, 389-399.	1.0	22
221	Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 10-23.	6.7	101
222	Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 1468-1476.	6.7	158
223	Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis. Circulation Research, 2004, 95, 109-116.	2.0	276
224	Deciphering Pro-angiogenic Transcription Factor Profiles in Hypoxic Human Endothelial Cells by Combined Bioinformatics and in vitro Modeling. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0